100 related articles for article (PubMed ID: 15023532)
1. The opioid agonist ethylketocyclazocine reverts the rapid, non-genomic effects of membrane testosterone receptors in the human prostate LNCaP cell line.
Kampa M; Papakonstanti EA; Alexaki VI; Hatzoglou A; Stournaras C; Castanas E
Exp Cell Res; 2004 Apr; 294(2):434-45. PubMed ID: 15023532
[TBL] [Abstract][Full Text] [Related]
2. A rapid, nongenomic, signaling pathway regulates the actin reorganization induced by activation of membrane testosterone receptors.
Papakonstanti EA; Kampa M; Castanas E; Stournaras C
Mol Endocrinol; 2003 May; 17(5):870-81. PubMed ID: 12554777
[TBL] [Abstract][Full Text] [Related]
3. The human prostate cancer cell line LNCaP bears functional membrane testosterone receptors that increase PSA secretion and modify actin cytoskeleton.
Kampa M; Papakonstanti EA; Hatzoglou A; Stathopoulos EN; Stournaras C; Castanas E
FASEB J; 2002 Sep; 16(11):1429-31. PubMed ID: 12205037
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-8 confers androgen-independent growth and migration of LNCaP: differential effects of tyrosine kinases Src and FAK.
Lee LF; Louie MC; Desai SJ; Yang J; Chen HW; Evans CP; Kung HJ
Oncogene; 2004 Mar; 23(12):2197-205. PubMed ID: 14767470
[TBL] [Abstract][Full Text] [Related]
5. Rho/ROCK/actin signaling regulates membrane androgen receptor induced apoptosis in prostate cancer cells.
Papadopoulou N; Charalampopoulos I; Alevizopoulos K; Gravanis A; Stournaras C
Exp Cell Res; 2008 Oct; 314(17):3162-74. PubMed ID: 18694745
[TBL] [Abstract][Full Text] [Related]
6. Rapid membrane effect of testosterone in LNCaP cells.
Wang Z; Liu L; Hou J; Wen D; Yan C; Pu J; Ouyang J; Pan H
Urol Int; 2008; 81(3):353-9. PubMed ID: 18931557
[TBL] [Abstract][Full Text] [Related]
7. Novel oligomeric proanthocyanidin derivatives interact with membrane androgen sites and induce regression of hormone-independent prostate cancer.
Kampa M; Theodoropoulou K; Mavromati F; Pelekanou V; Notas G; Lagoudaki ED; Nifli AP; Morel-Salmi C; Stathopoulos EN; Vercauteren J; Castanas E
J Pharmacol Exp Ther; 2011 Apr; 337(1):24-32. PubMed ID: 21205921
[TBL] [Abstract][Full Text] [Related]
8. Steroid hormonal regulation of growth, prostate specific antigen secretion, and transcription mediated by the mutated androgen receptor in CWR22Rv1 human prostate carcinoma cells.
Attardi BJ; Burgenson J; Hild SA; Reel JR
Mol Cell Endocrinol; 2004 Jul; 222(1-2):121-32. PubMed ID: 15249132
[TBL] [Abstract][Full Text] [Related]
9. ErbB-2 signaling is involved in regulating PSA secretion in androgen-independent human prostate cancer LNCaP C-81 cells.
Lee MS; Igawa T; Yuan TC; Zhang XQ; Lin FF; Lin MF
Oncogene; 2003 Feb; 22(5):781-96. PubMed ID: 12569372
[TBL] [Abstract][Full Text] [Related]
10. Growth inhibition and differentiation in human prostate carcinoma cells induced by the vitamin D analog 1alpha,24-dihydroxyvitamin D2.
Bauer JA; Thompson TA; Church DR; Ariazi EA; Wilding G
Prostate; 2003 May; 55(3):159-67. PubMed ID: 12692781
[TBL] [Abstract][Full Text] [Related]
11. Activation of membrane androgen receptors potentiates the antiproliferative effects of paclitaxel on human prostate cancer cells.
Kampa M; Kogia C; Theodoropoulos PA; Anezinis P; Charalampopoulos I; Papakonstanti EA; Stathopoulos EN; Hatzoglou A; Stournaras C; Gravanis A; Castanas E
Mol Cancer Ther; 2006 May; 5(5):1342-51. PubMed ID: 16731768
[TBL] [Abstract][Full Text] [Related]
12. The antiproliferative effect of opioid receptor agonists on the T47D human breast cancer cell line, is partially mediated through opioid receptors.
Hatzoglou A; Bakogeorgou E; Castanas E
Eur J Pharmacol; 1996 Jan; 296(2):199-207. PubMed ID: 8838457
[TBL] [Abstract][Full Text] [Related]
13. Coexpression of the partial androgen receptor enhances the efficacy of prostate-specific antigen promoter-driven suicide gene therapy for prostate cancer cells at low testosterone concentrations.
Suzuki S; Tadakuma T; Asano T; Hayakawa M
Cancer Res; 2001 Feb; 61(4):1276-9. PubMed ID: 11245419
[TBL] [Abstract][Full Text] [Related]
14. Androgen receptor signaling and vitamin D receptor action in prostate cancer cells.
Murthy S; Agoulnik IU; Weigel NL
Prostate; 2005 Sep; 64(4):362-72. PubMed ID: 15754350
[TBL] [Abstract][Full Text] [Related]
15. Regulation of prostate-specific antigen by activin A in prostate cancer LNCaP cells.
Fujii Y; Kawakami S; Okada Y; Kageyama Y; Kihara K
Am J Physiol Endocrinol Metab; 2004 Jun; 286(6):E927-31. PubMed ID: 14761877
[TBL] [Abstract][Full Text] [Related]
16. Conjugated and non-conjugated androgens differentially modulate specific early gene transcription in breast cancer in a cell-specific manner.
Notas G; Pelekanou V; Castanas E; Kampa M
Steroids; 2010; 75(8-9):611-8. PubMed ID: 19857505
[TBL] [Abstract][Full Text] [Related]
17. The inhibitory effect of opioids on HepG2 cells is mediated via interaction with somatostatin receptors.
Notas G; Kampa M; Nifli AP; Xidakis K; Papasava D; Thermos K; Kouroumalis E; Castanas E
Eur J Pharmacol; 2007 Jan; 555(1):1-7. PubMed ID: 17113072
[TBL] [Abstract][Full Text] [Related]
18. Prosaposin upregulates AR and PSA expression and activity in prostate cancer cells (LNCaP).
Koochekpour S; Lee TJ; Wang R; Culig Z; Delorme N; Caffey S; Marrero L; Aguirre J
Prostate; 2007 Feb; 67(2):178-89. PubMed ID: 17044040
[TBL] [Abstract][Full Text] [Related]
19. Androgen receptor protein is down-regulated by basic fibroblast growth factor in prostate cancer cells.
Cronauer MV; Nessler-Menardi C; Klocker H; Maly K; Hobisch A; Bartsch G; Culig Z
Br J Cancer; 2000 Jan; 82(1):39-45. PubMed ID: 10638964
[TBL] [Abstract][Full Text] [Related]
20. Prostate cancer cells (LNCaP) generated after long-term interleukin 6 (IL-6) treatment express IL-6 and acquire an IL-6 partially resistant phenotype.
Hobisch A; Ramoner R; Fuchs D; Godoy-Tundidor S; Bartsch G; Klocker H; Culig Z
Clin Cancer Res; 2001 Sep; 7(9):2941-8. PubMed ID: 11555613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
